🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Oxford Nanopore Technologies plc (LON:ONT)
United Kingdom flag United Kingdom · Delayed Price · Currency is GBP · Price in GBX
188.70
-10.80 (-5.41%)
Nov 20, 2026, 4:35 PM GMT
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

The strategy concentrates on high-value research, biopharma and clinical applications, using partnerships to support validation and access. Targets include adjusted EBITDA break-even in 2027, positive growing free cash flow from 2028 and revenue above $700m by 2030.

Operator

Good morning, and welcome to Jefferies 2026 Global Healthcare Conference. It is my pleasure to introduce the CEO and the CFO of Oxford Nanopore Technologies. Thank you very much.

Francis Van Parys
CEO, Oxford Nanopore Technologies

Good morning, and thank you for joining us. I joined Oxford Nanopore because I saw the opportunity to create an extraordinary business with a technology that can really and truly change our understanding of biology. We read native DNA and RNA directly, with protein analysis on the horizon, on the same platform. This opens opportunities well beyond conventional sequencing. We already serve customers in more than 125 countries. We have more than 1,350 people at the business now, and about 3,100 active patents. With 20,000 publications and more coming, customers demonstrate really how broadly this technology can be used. Our job is to turn that into broader adoption and into profitable growth. Today, I will explain our choices, the changes we are making, and why the opportunity extends beyond 2030.

We already have a global business across Americas, APAC, and Europe, where we have the strongest market share in terms of our performance. Around 2/3 of our revenue comes from consumables. Each time a customer uses our platform and broader adoption materializes, our revenue opportunity increases. Today, research accounts for about 2/3 of our revenue. We have about 1/3 in applied markets such as biopharma and diagnostics. They start from smaller bases. They are already growing at a faster pace, and by 2030, we expect clinical and biopharma to reach about 2/3 of our revenue in total. Why do customers choose Oxford Nanopore? It really starts from the information we provide from the platform. The Oxford Nanopore platform has three major areas of differentiation.

We deliver richer insights, we deliver answers at a faster pace, and we deliver technology that is accessible in a centralized as well as in a decentralized setting. Long and ultra-long reads, DNA reads, and they resolve complex regions, and they resolve structural changes, which helps with understanding of disease progression, disease mechanisms, specifically in rare disease. We read native methylation alongside the DNA sequence, which brings genetic and epigenetic information together in one run. We read RNA directly. In mRNA quality control, that means assessing several quality attributes in one run, where customers have traditionally used multiple technologies to achieve the same outcome. The data arrives in real time.

That means that customers can choose how much data they want to process and want to get as output from the system, as well as choosing the context and the setting in which they use the technology, which is enabled by the scalable nature of our platform. This is why this is a molecular sensing platform with opportunities beyond just sequencing. Our focus is on the applications where that difference creates the greatest value for our customers. We have set our strategy around four priorities. These priorities are shaping how we run the business every day. Starting with customer-centric growth. We focus on high-value applications where the technology can make a meaningful difference and create the best value. That means starting with the customer's problem and being very clear about where we can win. That informs our innovation strategy.

The focused innovation is about turning that into a product portfolio that is simpler, that is more focused towards the opportunity that the market offers, and that delivers a roadmap with products and workflows that customers can readily adopt. Disciplined execution. We have seen over the last couple of years how the finance function has delivered cost discipline and delivered margin improvements that bring us to where we are today, and I will speak about the financial a little later. We are now expanding that across the business and making sure we deliver with rigor, with a connected strategy that is linked to what we want to achieve based on the strategy we have set out in the first pillar. Finally, a high-performance culture. Every priority has a named owner. We are building clear accountability in the business across the functions, backed by a leadership team with experience to deliver.

These changes connect our strategy to the decisions we make about products, people, and investment. The opportunity is large. To build a successful business, though, we have to be clear about where we will win. We assess each application of the technology on how differentiated our value is and how readily customers can adopt it. We have a serviceable market of about $14 billion-$16 billion, but that doesn't really mean anything in terms of what we can achieve. We are concentrating, therefore, on three markets across approximately 18 priority applications. Research whole-genome sequencing methylation, where long-reads and native methylation make a difference into biological insights, is where we have a strong foundation and where we will continue to focus. In biopharma, we can simplify R&D, drug discovery, and quality control by replacing established technologies in one particular sequencing run. In clinical, we are selective.

Rare disease, oncology, specifically tumors profiling, as well as infectious disease are the areas of focus, and this is where partners can help us accelerate our progress in terms of delivery. By doing so, the opportunity doesn't become smaller, it becomes more focused. Our choices are becoming clearer. Let me show you in terms of the next couple of examples. Let's take a personalized mRNA vaccine. The manufacturer needs to know that the sequence is right for the patient, the transcripts are intact, and the material meets the required quality attributes. Today, answering those questions can mean several methods, instruments, and data systems, with time-consuming work at every handoff. We have demonstrated that one Oxford Nanopore run can bring multiple measurements together in a comprehensive report, including sequence, transcript integrity, and features such as the poly-A tail.

For the customer, it means a more complete picture of product quality through a simpler workflow, with the potential to reduce testing time as well as the cost. Our focus now is to turn that capability into a dependable, validated, and audit-ready workflow that withstands the scrutiny of a GMP environment. That is why our opportunity reaches beyond sequencing. We can address a customer need currently served by several different technologies. Same opportunity exists in clinical. In this acute leukemia study, researchers have brought together information from eight different pathology assays into one Oxford Nanopore adaptive sampling run. That includes genetic information, variation, and methylation, giving a broader view of the disease within a single workflow. The potential economics are also compelling. Estimated reagent and consumable costs were about $350-$450 per sample, compared to $1,650-$2,050 across conventional assays.

The next step is to make this something laboratories can use with confidence, with the necessary evidence, reliable reporting, and integration into their systems. Partners can help us get there. The study shows how richer information can deliver value in a simpler workflow, and how we bring that to market matters just as much. We do not need to build every element of the workflow. Where our differentiation and capabilities are strongest, in research, in biopharma QC, we can capture the full value, own the solution, and capture the full product economics. Where others bring validation, regulatory deployment, or market access, that is where we partner. Lonza in GMP as an example for mRNA quality control, MyOme and Natera company, in rare disease, who help us with LDT enablement. Licensing gives us another route, with relatively limited capital.

Our August cross-licensing agreement with a global diagnostics company strengthens our IP portfolio and brings $20 million of upfront licensing revenue in 2026, as well as $15 million of product purchases across 2027 and 2028. The larger opportunity, though, is the royalty stream. We have a royalty stream, low to single-digit rates on the relevant counterparty revenues for the life of the patents. Based on analyst expectations for those sales, we believe that about 90% of the economic value lies in the royalty stream that we have secured. We retain control where it matters, where we have our core capabilities, and we partner where it improves speed, reach, or returns. We built a leadership team to deliver on this strategy, combining Oxford Nanopore scientific depth with experience in scaling a global business.

That builds on Lakmal's scientific expertise, Nick's finance and operational experience, and the team that is with Oxford Nanopore for a long period of time. But since I joined, we have added capability across the team, including people, or functions of people, product, medical affairs, information technology, and marketing and communications. Our first Chief Medical Officer, Davide Manissero, joined us in August and reflects our focus on clinical. Our first Chief Information Officer, Andrew Watson, brings the experience to strengthen the systems we need to scale. Our latest appointment, Sebastian Kronmüller, joins us from Philips and brings experience from Siemens Healthineers and Philips in the business development function to help us realize revenue opportunities, partnerships, and inorganic opportunities. He will join at the beginning of January next year. Across the team, we have the experience to execute.

I am confident that we are building the team that can deliver on that strategy, and the expectation is clear: take ownership, work across functions, and deliver consistently against the strategy. Let us connect that to profitability. We have already improved the economics of our products, and we see further scope ahead. Consumables margins have dramatically improved from 2023 at about 64% to around 75%. We see further opportunity to expand those margins towards 80% and more. Devices and services margins have moved from about 23% - 34%, and again, we see longer-term potential towards approximately 40%. The reasons we have been able to do this is through pricing, yield improvements, recycling, and the scale of broader adoption. Further opportunities include increased recycling of the PromethION flow cell, portfolio simplification, as well as better absorption of service costs.

We have specific ways to improve product economics as adoption grows, and this gives us a stronger foundation for profitability. Our adjusted EBITDA losses have narrowed materially since the end of 2023, which reflects a mix of strong revenue growth, improving gross margin, and stronger cost discipline. Most importantly, we are making good progress towards our adjusted EBITDA break-even targets for 2027. Delivery depends on growing adoption, improving gross margin further, and keeping the control of costs a standard of operating. That is why these operating changes really matter. A focused portfolio helps us put investments where it can make the greatest difference, and a more consistent delivery helps us serve a larger business efficiently. Break-even is just a step along the way. We need discipline in investments and working capital to turn that progress into cash generation.

By 2030, we are targeting more than $700 million of revenue and an adjusted EBITDA margin of 15% above, with positive growing free cash flow from 2028. Research is our largest market today and will remain a significant contributor through 2030. It is expected to grow more slowly than clinical and biopharma, but from a much larger base. Clinical and biopharma are expected to grow faster and become a greater share of group revenue towards two-thirds of revenue in 2030, as I mentioned earlier. The framework is organic, and the signed agreement royalty stream is excluded from these numbers, and further business development and licensing opportunities could add upside. Delivering those targets means driving greater customer adoption, building the evidence, and establishing the clinical pathways needed to scale. But 2030 is not the end of our ambition.

We believe that we can build a $1 billion plus revenue business over time. We are not putting a timeframe towards that. We are focused on delivering near term while at the same time building the capabilities that can grow beyond the $700 million that we project for 2030. Let me leave you with four points. We have a differentiated molecular sensing platform with opportunities that go beyond traditional sequencing. We have made clear strategic choices, and we are translating them into how the business operates. We have built an experienced leadership team to execute the strategy. We have a path towards profitability and clear 2030 milestones, with royalty upside outside those targets and a larger opportunity beyond them. Look, I am an operator at heart. I believe in this strategy.

The confidence comes from where the technology has evolved to today and where it has come from, the execution that is being secured by an experienced management team, and the customer problems we can clearly solve. My focus is now on delivery, enabling broader adoption, and turning this into sustainable value for shareholders and customers. Thank you, and we will take questions now.

Speaker 3

Hi. Thanks so much for the presentation. Just one, as you are seeing competitive-wise in the landscape, we have seen a lot more entrants and kind of hubbub in the long-read technology space from Illumina TruPath, and PacBio lowering price. I guess, when you talk to your customers, what are some of the things and feedback that you get, whether it is expanding more into multiomics or differentiating against some of the new technologies?

Francis Van Parys
CEO, Oxford Nanopore Technologies

Mm-hmm. Not sure if the long-read space is getting a lot more intense in terms of competition. We see a lot more of that, a lot more happening in the short-read space. The applications we focus on are where the technology can make the greatest difference, and we believe we have a strong competitive position against the established players in that space. This being said, we do not stand still, and we need to continue to evolve the platform continuously. In order to deliver on this strategy, we do not need a new platform. We need to incrementally improve its capabilities, simplify the workflow, the ease of use, and close a couple of gaps related to things like bioinformatics. I think if we do that well, we can deliver in those applications where we have put our focus.

Speaker 4

I was wondering if you are considering AI providers or Frontier Labs as potential customers, because your platform actually generates raw biological data, and they are willing to spend a lot of money in order to train these models. Any comments on these set of customers potentially?

Francis Van Parys
CEO, Oxford Nanopore Technologies

Yeah, sure. Thank you for the question. I will start, and I will leave Nick also to add some color. You make a great point. We believe we deliver the richest sequencing data with our capabilities in native DNA and RNA, transcriptomics, genomics, metabolomics, and soon to be proteomics. We are going to help build datasets that we believe these agentic models need to be trained on. That is certainly going to provide us with an opportunity. How big exactly that is going to be remains to be seen. We also want to remain balanced in terms of jumping on the bandwagon, while at the same time being clear on what we deliver and what value we can create in that segment. Clearly, it is going to be a tailwind for us. We see it already in incoming interest and inbound partnerships that we can consider.

Nick Keher
CFO, Oxford Nanopore Technologies

Yeah, just to add as well, it is a big ecosystem, and so we are having conversations across with multiple parties. You have the well-known foundational labs that are out there that are looking at this. You have the data infrastructure players as well, which is quite interesting, and that we are already seeing some of them as customers. Then you have the service providers that are looking to kind of play a part in all of this as well, as well as actually the people who have the samples. It is a multitude of people that we are having conversations with or already generating revenue from, because actually, this AI wave, it has not just started yesterday. It has actually been building for quite some time. Actually, those datasets have been building for some time internally within certain companies as well. So we have already been supplying to these people.

But to Francis' point, we kind of want to be very careful with our messaging in terms of our position in all of this as well, because otherwise, this could be something that gets a lot of attention at the wrong time. So we want to be considered. Absolutely, there are other conversations happening, and we probably want to update more in due course when we can point to things as well where people realize the value. I would be very balanced on it. There is this debate still raging, which is that we clearly believe and see that we can generate richness of information that is above other technologies, but there is a scale element as well that people are kind of looking at, which is the high throughput nature and generating a lot of data, but we would argue the wrong data. That is still raging, that argument as well.

Speaker 4

I got one more. I was wondering if you could comment a bit on the progress of what you've been thinking with regard to protein sequencing.

Francis Van Parys
CEO, Oxford Nanopore Technologies

Yeah, sure. We're making good continued progress. We have two phases in that development. One focused more on the peptide sequencing, which has a number of interesting applications. I think the holy grail is really in the de novo protein sequencing, which is a little bit further along. We are making, from a scientific standpoint and a research standpoint, the progress that we were hoping to make. The question is now, how do we move away from just doing what's scientifically possible to targeting and towards a market opportunity that is well-defined and that develops products that serve customers' needs and the real biological questions, rather than doing it for technology development's sake?

Speaker 6

Can you maybe, I mean, you just came in, right? Oxford Nanopore is around for a longer time, was a bit more prominent a couple of while ago. Can you comment on what went wrong in the past and what you would have done differently?

Francis Van Parys
CEO, Oxford Nanopore Technologies

Yeah. Well, I'm not sure if my role is to look back too much. However, this being said, look, the platform has matured through the years, was developed for research applications, and that transpired into the culture of the company to enable analysis in different settings for a variety of applications. That has allowed the technology to mature to a level to where we are today. That being said, there was perhaps insufficient focus on where the technology make the greatest difference and can create the greatest value. By doing so, you're not doing those key workflows as well as you could, because if you want to be successful in a GMP environment, in a clinical space, different rules, different expectations, regulatory environments, GMP rigor.

That is not something that was necessarily a capability within the company and that we are developing because we believe if the company needs to scale, which it does, it is going to be by focusing on those high-value applications. That is the pivot we are making. I consider being lucky to be in this point, that the maturity of the technology is there to be delivered on. Now, it is time to deliver on the commercial opportunity and the science that was created.

Speaker 6

Great.

Francis Van Parys
CEO, Oxford Nanopore Technologies

Good.

Speaker 6

Yeah.

Francis Van Parys
CEO, Oxford Nanopore Technologies

Our clock says 00:06. Thank you for your time. Appreciate the interest.